Compositions and methods using microspheres and non-ionic contrast agents
The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.
1. A substantially spherical microsphere, comprising:
a biocompatible polymeric material comprising a polymer or copolymer prepared from one or more acrylate monomers,
a drug selected from at least one of the following: daunorubicin, daunomycin, doxorubicin, irinotecan, and topotecan, wherein the concentration of drug is between about 1 mg to about 400 mg of drug per 100 mg of dry microspheres, and
a non-ionic contrast agent containing iodine, wherein the concentration of non-ionic contrast agent is between about 100 mg to about 3200 mg iodine per 100 mg of dry microspheres, wherein the non-ionic contrast agent is selected from at least one of the following: metrizamide, iopamidol, iodixanol, iohexol, ioversol, iopromide, iobitridol, iomeprol, iopentol, iopamiron, ioxilan, iotrolan, iotrol, and combinations thereof
wherein the microsphere is swellable in a pharmaceutically acceptable solution and has a diameter of from about 10 μm to about 1000 μm before swelling wherein the diameter of the microsphere is from about 40 μm to about 2000 μm after swelling.
2. The microsphere of claim 1 , wherein the non-ionic contrast agent is selected from at least one of the following: X-ray, CT, paramagnetic and superparamagnetic contrast agents.
3. The microsphere of claim 1 , wherein the polymeric material comprises a hydrolyzed polyacrylic acid ester.
4. The microsphere of claim 1 , wherein the polymeric material comprises a carboxylic acid.
5. The microsphere of claim 1 , wherein the concentration of the drug is from about 10 mg to about 400 mg of drug per 100 mg of dry microspheres.
6. The microsphere of claim 1 , wherein the concentration of the non-ionic contrast agent is from about 100 mg to about 1500 mg iodine per 100 mg of dry microspheres.
7. The microsphere of claim 1 , wherein between about 10% and about 100% of the drug is configured to be released from the microsphere within a period of between about 3 hours and about 10 weeks following administration to a patient.
8. A substantially spherical microsphere, comprising:
a biocompatible polymeric material comprising a polymer or copolymer prepared from one or more acrylate monomers,
doxorubicin, wherein the concentration of doxorubicin is between about 1 mg to about 400 mg of drug per 100 mg of dry microspheres, and
a non-ionic contrast agent containing iodine, wherein the concentration of non-ionic contrast agent is between about 100 mg to about 3200 mg iodine per 100 mg of dry microspheres, wherein the non-ionic contrast agent is selected from at least one of the following: metrizamide, iopamidol, iodixanol, iohexol, ioversol, iopromide, iobitridol, iomeprol, iopentol, iopamiron, ioxilan, iotrolan, iotrol, and combinations thereof,
wherein the microsphere is swellable in a pharmaceutically acceptable solution and has a diameter of from about 10 μm to about 1000 μm before swelling wherein the diameter of the microsphere is from about 40 μm to about 2000 μm after swelling.
9. The microsphere of claim 8 , wherein the polymeric material comprises a hydrolyzed polyacrylic acid ester.
10. The microsphere of claim 8 , wherein the polymeric material comprises a carboxylic acid.
11. The microsphere of claim 8 , wherein the concentration of the doxorubicin is from about 10 mg to about 400 mg of doxorubicin per 100 mg of dry microspheres.
12. The microsphere of claim 8 , wherein the concentration of the non-ionic contrast agent is from about 100 mg to about 1500 mg iodine per 100 mg of dry microspheres.
13. The microsphere of claim 8 , wherein more than 1% but less than 20% of the doxorubicin is configured to be released from within the microsphere within a period of 72 hours.
14. The microsphere of claim 8 , wherein between about 10% and about 100% of the doxorubicin is configured to be released from the microsphere within a period of between about 3 hours and about 10 weeks following administration to a patient.
15. The microsphere of claim 1 , wherein the polymer or copolymer is prepared from one or more methacrylate monomers.
16. The microsphere of claim 8 , wherein the polymer or copolymer is prepared from one or more methacrylate monomers.